No metabolic derangement, insulin sensitivity preserved; fat on the macrometabolic level can look fit. Now, let's look deeper.
Novel Oral Antiobesity Drug Shown to Reduce Body Weight by up to 13% in First-In-Human Study
EASD 2024: Amycretin was also found to be safe and well tolerated in adults with obesity and without diabetes.
Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care
Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.
Mental Health Among Adolescents With Obesity: Daily Dose
Your daily dose of the clinical news you may have missed.
Obesity & Type 2 Diabetes: An Expert Discussion
In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.
Survodutide: Novel GCGR/GLP-1RA Shows Promise in Obesity, MASH Treatment
EASD 2024: New data shows survodutide may be beneficial for persons with obesity and MASH.
Novel GLP-1 RA for Obesity Shows Promise in Early Phase 1 Trial
Once-daily oral TERNS-601 was associated with a significant mean 5% weight reduction after 28 days and had a favorable tolerability profile.